Cargando…

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase

INTRODUCTION: The aim of this work is to evaluate the impact of the timing of pre-infusion serum uric acid (sUA) test results for use in applying stopping rules for pegloticase to identify patients at risk for infusion reactions (IRs) while on therapy. METHODS: Data from the phase 3 clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keenan, Robert T., Baraf, Herbert S. B., LaMoreaux, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513953/ https://www.ncbi.nlm.nih.gov/pubmed/30875075 http://dx.doi.org/10.1007/s40744-019-0151-9

Ejemplares similares

Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices
por: Majjhoo, Amar, et al.
Publicado: (2019)

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
por: Baraf, Herbert S. B., et al.
Publicado: (2014)

Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023)

Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
por: Morton, Allan H., et al.
Publicado: (2018)

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study
por: Albert, John A., et al.
Publicado: (2020)

Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
por: Masri, Karim Richard, et al.
Publicado: (2022)

Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
por: Broadwell, Aaron, et al.
Publicado: (2022)

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout
por: Calabrese, Leonard H., et al.
Publicado: (2017)

Long-term safety of pegloticase in chronic gout refractory to conventional treatment
por: Becker, Michael A, et al.
Publicado: (2013)

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
por: Botson, John K., et al.
Publicado: (2022)

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
por: Botson, John K., et al.
Publicado: (2022)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
por: Botson, John K., et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
por: Botson, John K., et al.
Publicado: (2023)

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
por: Baraf, Herbert SB, et al.
Publicado: (2013)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

First-Dose Antimicrobial Infusion Reactions in Patients Enrolled in Outpatient Parenteral Antimicrobial Therapy Services
por: Kovacik, Carrie N, et al.
Publicado: (2023)

Residual Infusion Performance Evaluation (RIPE): A Single-Center Evaluation of Residual Volume Post-Intravenous Eravacycline Infusion
por: Baumann, Alysa J., et al.
Publicado: (2023)

Serum uric acid levels during leprosy reaction episodes
por: Morato-Conceicao, Yvelise T., et al.
Publicado: (2016)

Use of dexmedetomidine infusion in anaesthesia for awake craniotomy
por: Kallapur, Basavaraj G, et al.
Publicado: (2012)

Furosemide infusion in children with dengue fever and hypoxemia
por: Bharath Kumar Reddy, K. R., et al.
Publicado: (2014)

Pre-treatment with compound Danshen dripping pills prevents lipid infusion-induced microvascular dysfunction in mice
por: Zhang, Yanda, et al.
Publicado: (2020)

Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design
por: Mease, Kirsten M., et al.
Publicado: (2017)

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study
por: Botson, John K., et al.
Publicado: (2022)

New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012)

Serum uric acid a depression biomarker
por: Meng, Xiandong, et al.
Publicado: (2020)

Night‐Time Apomorphine Infusion: Who Are the Best Candidates?
por: Cochen De Cock, Valérie, et al.
Publicado: (2023)

Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions
por: Arastu, Asad H., et al.
Publicado: (2022)

Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection
por: Martinez, Mario A, et al.
Publicado: (2022)

PEG-ing down (and preventing?) the cause of pegloticase failure
por: Abeles, Aryeh M
Publicado: (2014)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

Infliximab-Related Infusion Reactions: Systematic Review
por: Lichtenstein, Lev, et al.
Publicado: (2015)

Pyrogenic Reactions Following Intravenous Saline Infusions
por: Paul, B. M., et al.
Publicado: (1944)

Pyrogenic Reactions Following Intravenous Saline Infusions
por: Shah, M. A.
Publicado: (1944)

Roadmap and strategy for overcoming infusion reactions to nanomedicines
por: Szebeni, Janos, et al.
Publicado: (2018)

An AP Perspective on Infusion Reactions in the Era of Immunotherapy
por: Peterson, Carrie
Publicado: (2022)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

The Effects of Intravenous Fluid Viscosity on the Accuracy of Intravenous Infusion Flow Regulators
por: Ko, Eunji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_50erb8d47or8r961ik0druskka